CD22 CAR mRNA
cis a chimeric antigen receptor mRNA targeting CD22. When delivered via CD8-targeted LNP, CD22 CAR mRNA inhibits tumor growth in Nalm6 tumor-bearing mouse models. CD22 CAR mRNA can be used for research on hematologic malignancies.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG MHC I/II KO mice (female, 10 weeks old, engrafted with luciferase-expressing Nalm6 cells and human PBMCs)[1]
-
Dosage:0.3 mg/kg
-
Administration:i.v.; 5 doses on days 7, 11, 14, 18, 21
-
Result:Decreased average radiance to approximately 6 × 106 p/s/cm2/sr on day 26, compared to >2 × 107 p/s/cm2/sr in control groups.
Eliminated all CD22-expressing tumor cells from the spleen and liver.
Chemical Information
-
SMILES
[CD22 CAR mRNA]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CD22 CAR mRNA Related Classifications
HY-188021 Related Classifications
Powered by Bioz